Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer

Xin-Hua Xu; Jin Su; Xiang-Yang Fu; Feng Xue; Qiao Huang; Dao-Jun Li; Ming-Qian Lu

首页> 外文期刊>Cancer Chemotherapy and Pharmacology >Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer

【24h】

Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer

机译：厄洛替尼作为一线治疗亚洲老年晚期非小细胞肺癌患者的临床疗效

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose To evaluate the efficacy and toxicities of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer (NSCLC).

机译：目的评估厄洛替尼作为一线治疗亚洲晚期老年非小细胞肺癌（NSCLC）患者的疗效和毒性。

著录项

来源
《Cancer Chemotherapy and Pharmacology》 |2011年第2期|p.475-479|共5页
作者
Xin-Hua Xu; Jin Su; Xiang-Yang Fu; Feng Xue; Qiao Huang; Dao-Jun Li; Ming-Qian Lu;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer. [J] . Xu XH, Su J, Fu XY, Cancer chemotherapy and pharmacology. . 2011,第2期

机译：厄洛替尼作为一线治疗亚洲老年晚期非小细胞肺癌患者的临床效果。
2. BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer [J] . Gridelli Cesare, Rossi Antonio, Ciardiello Fortunato, Clinical lung cancer . 2016,第5期

机译：贝弗利：比较贝伐单抗加厄洛替尼与单独厄洛替尼作为EGFR突变晚期非鳞状非小细胞肺癌患者的一线治疗的随机开放标签III期试验的理论和设计
3. An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial. [J] . Gridelli C, Butts C, Ciardiello F, Clinical lung cancer . 2008,第4期

机译：国际，多中心，随机，III期研究对晚期非小细胞肺癌一线埃罗替尼，二线顺铂/吉西他滨与一线顺铂/吉西他滨，二线埃洛替尼进行二线研究：治疗原理和方案动态TORCH审判。
4. Effects of Erlotinib after Acquired Resistance to Gefitinib in Advanced Non-small-cell Lung Cancer [C] . Pan Jingjing, Shi Meiqi, Feng Jifeng Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference on . 2012

机译：吉非替尼耐药对晚期非小细胞肺癌患者的厄洛替尼治疗效果
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer [O] . Feng Wen, Hanrui Zheng, Pengfei Zhang, 2018

机译：基于OPTIMAL和ENSURE试验的厄洛替尼与化疗联合治疗亚洲非鳞状非小细胞肺癌一线患者的成本效益分析
7. OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer [O] . Feng Wen, Hanrui Zheng, Pengfei Zhang, 2018

机译：欧洲非鳞状非小细胞肺癌的亚洲患者综合治疗基于试验的欧洲患者的综合性成本效果分析

Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer

摘要

著录项

相似文献

相关主题

期刊订阅